MARKET

TARO

TARO

Taro Pharmaceutical Inds Ltd
NYSE

Real-time Quotes | Nasdaq Last Sale

37.37
+0.11
+0.28%
Opening 12:15 07/07 EDT
OPEN
37.43
PREV CLOSE
37.26
HIGH
38.06
LOW
37.00
VOLUME
12.04K
TURNOVER
290.01K
52 WEEK HIGH
74.29
52 WEEK LOW
33.59
MARKET CAP
1.40B
P/E (TTM)
24.06
1D
5D
1M
3M
1Y
5Y
Taro Pharmaceutical Industries Ltd. (NYSE:TARO) Stock Is Going Strong But Fundamentals Look Uncertain: What Lies Ahead ?
Taro Pharmaceutical Industries' (NYSE:TARO) stock is up by a considerable 9.5% over the past month. But the company's...
Simply Wall St. · 1d ago
Taro Pharmaceutical GAAP EPS of $0.73, revenue of $143.26M
Taro Pharmaceutical press release (NYSE:TARO): Q4 GAAP EPS of $0.73. Revenue of $143.26M (-3.4% Y/Y).
Seekingalpha · 05/27 06:10
Taro Pharmaceutical Industries Swings to Fiscal Q4 Profit, Sales Fall
MT Newswires · 05/27 04:24
BRIEF-Taro Reports Qtrly Diluted Earnings Per Share Of $0.73
reuters.com · 05/26 23:03
Taro Provides Results for the Year Ended March 31, 2022
HAWTHORNE, N.Y., May 26, 2022--TARO PROVIDES RESULTS FOR THE YEAR ENDED MARCH 31, 2022
Business Wire · 05/26 23:00
Taro Pharmaceutical Q1 2022 Earnings Preview
Taro Pharmaceutical (NYSE:TARO) is scheduled to announce Q1 earnings results on Thursday, May 26th, after market close. The consensus EPS Estimate is $0.88 (+8.6% Y/Y) and the consensus Revenue Estimate
Seekingalpha · 05/25 21:35
Notable earnings after Thursday's close
ADSK, AEO, COST, DELL, DOMO, FTCH, GPS, LGF.A, LIZI, MAXN, ME, MRVL, RRGB, SUMO, SVM, TARO, ULTA, VMW, WDAY, ZS For Seeking Alpha's full earnings season calendar, click here.
Seekingalpha · 05/25 21:35
Taro Pharmaceutical Indus Earnings Preview
Taro Pharmaceutical Indus (NYSE:TARO) is set to give its latest quarterly earnings report on Thursday, 2022-05-26. Here's what investors need to know before the announcement. Analysts estimate that Taro Pharmaceutical Indus will report an earnings per shar...
Benzinga · 05/25 17:09
More
No Data
Learn about the latest financial forecast of TARO. Analyze the recent business situations of Taro Pharmaceutical Inds Ltd through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

0.00%Strong Buy
100.00%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average TARO stock price target is 73.00 with a high estimate of 73.00 and a low estimate of 73.00.
High73.00
Average73.00
Low73.00
Current 37.37
EPS
Actual
Estimate
-0.150.210.560.92
Q1 2022
Q2 2022
Q3 2022
Q4 2022
Q1 2023
Institutional Holdings
Institutions: 129
Institutional Holdings: 5.19M
% Owned: 13.82%
Shares Outstanding: 37.58M
TypeInstitutionsShares
Increased
21
241.91K
New
7
194
Decreased
27
285.22K
Sold Out
7
28.90K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
+0.08%
Pharmaceuticals & Medical Research
+0.61%
Key Executives
Chairman/Director
Dilip Shanghvi
Chief Executive Officer/Director
Uday Baldota
Vice Chairman/Director
Abhay Gandhi
Vice President/General Counsel/Secretary
Erik Zwicker
Vice President/Director of Human Resources
Michele Visosky
Vice President
Victoria Chester
Vice President
Itamar Karsenti
Vice President - Research & Development
Avi Avramoff
Vice President - Business Development
Vikash Agarwal
Other
Jayesh Shah
Director
James Kedrowski
Director
Sudhir Valia
Independent Director
Linda Benshoshan
Independent Director
Dov Pekelman
Independent Director
Robert Stein
No Data
No Data
About TARO
Taro Pharmaceutical Industries Ltd. (Taro) is a science-based pharmaceutical company. The Company operates principally through three entities: Taro Pharmaceutical Industries Ltd. (Taro Israel), and two of its subsidiaries, Taro Pharmaceuticals Inc. (Taro Canada) and Taro U.S.A. The Company markets over 200 pharmaceutical products in over 25 countries. The Company's owned product brands include Rokacet, with generic names, such as acetaminophen, codeine and caffeine; Topicort, with the generic name, desoximetasone; Etopan, with the generic name etodolac, and Ovide, with the generic name, malathion, among others. The Company's other generic products include acetazolamide, adapalene, alclometasone dipropionate, amiodarone hydrochloride, ammonium lactate, augmented betamethasone dipropionate, cetirizine hydrochloride, clobetasol propionate, clomipramine hydrochloride, clorazepate dipotassium, fluorouracil, ketoconazole, metronidazole, mupirocin and warfarin sodium, among others.

Webull offers kinds of Taro Pharmaceutical Industries Ltd. stock information, including NYSE:TARO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TARO stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading TARO stock methods without spending real money on the virtual paper trading platform.